Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab
The identification of factors that respond to anti-angiogenic therapy would represent a significant advance in the therapeutic management of metastatic-colorectal-cancer (mCRC) patients. We previously reported the relevance of VEGF-A and some components of the renin–angiotensin-aldosterone system (R...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/13/3054 |
| _version_ | 1797480732484960256 |
|---|---|
| author | M. José Ortiz-Morales Marta Toledano-Fonseca Rafael Mena-Osuna M. Teresa Cano Auxiliadora Gómez-España Juan R. De la Haba-Rodríguez Antonio Rodríguez-Ariza Enrique Aranda |
| author_facet | M. José Ortiz-Morales Marta Toledano-Fonseca Rafael Mena-Osuna M. Teresa Cano Auxiliadora Gómez-España Juan R. De la Haba-Rodríguez Antonio Rodríguez-Ariza Enrique Aranda |
| author_sort | M. José Ortiz-Morales |
| collection | DOAJ |
| description | The identification of factors that respond to anti-angiogenic therapy would represent a significant advance in the therapeutic management of metastatic-colorectal-cancer (mCRC) patients. We previously reported the relevance of VEGF-A and some components of the renin–angiotensin-aldosterone system (RAAS) in the response to anti-angiogenic therapy in cancer patients. Therefore, this prospective study aims to evaluate the prognostic value of basal plasma levels of VEGF-A and angiotensin-converting enzyme (ACE) in 73 mCRC patients who were to receive bevacizumab-based therapies as a first-line treatment. We found that high basal VEGF-A plasma levels were significantly associated with worse overall survival (OS) and progression-free survival (FPS). On the other hand, low ACE levels were significantly associated with poor OS. Importantly, a simple scoring system combining the basal plasma levels of VEGF-A and ACE efficiently stratified mCRC patients, according to OS, into high-risk or low-risk groups, prior to their treatment with bevacizumab. In conclusion, our study supports that VEGF-A and ACE may be potential biomarkers for selecting those mCRC patients who will most benefit from receiving chemotherapy plus bevacizumab treatment in first-line therapy. Additionally, our data reinforce the notion of a close association between the RAAS and the anti-angiogenic response in cancer. |
| first_indexed | 2024-03-09T22:04:19Z |
| format | Article |
| id | doaj.art-3e878d056ea44d8a8ec1c125fcb221a6 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T22:04:19Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-3e878d056ea44d8a8ec1c125fcb221a62023-11-23T19:43:38ZengMDPI AGCancers2072-66942022-06-011413305410.3390/cancers14133054Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus BevacizumabM. José Ortiz-Morales0Marta Toledano-Fonseca1Rafael Mena-Osuna2M. Teresa Cano3Auxiliadora Gómez-España4Juan R. De la Haba-Rodríguez5Antonio Rodríguez-Ariza6Enrique Aranda7Medical Oncology Department, Reina Sofía University Hospital, 14004 Córdoba, SpainMaimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Córdoba, SpainMaimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Córdoba, SpainMedical Oncology Department, Reina Sofía University Hospital, 14004 Córdoba, SpainMedical Oncology Department, Reina Sofía University Hospital, 14004 Córdoba, SpainMedical Oncology Department, Reina Sofía University Hospital, 14004 Córdoba, SpainMedical Oncology Department, Reina Sofía University Hospital, 14004 Córdoba, SpainMedical Oncology Department, Reina Sofía University Hospital, 14004 Córdoba, SpainThe identification of factors that respond to anti-angiogenic therapy would represent a significant advance in the therapeutic management of metastatic-colorectal-cancer (mCRC) patients. We previously reported the relevance of VEGF-A and some components of the renin–angiotensin-aldosterone system (RAAS) in the response to anti-angiogenic therapy in cancer patients. Therefore, this prospective study aims to evaluate the prognostic value of basal plasma levels of VEGF-A and angiotensin-converting enzyme (ACE) in 73 mCRC patients who were to receive bevacizumab-based therapies as a first-line treatment. We found that high basal VEGF-A plasma levels were significantly associated with worse overall survival (OS) and progression-free survival (FPS). On the other hand, low ACE levels were significantly associated with poor OS. Importantly, a simple scoring system combining the basal plasma levels of VEGF-A and ACE efficiently stratified mCRC patients, according to OS, into high-risk or low-risk groups, prior to their treatment with bevacizumab. In conclusion, our study supports that VEGF-A and ACE may be potential biomarkers for selecting those mCRC patients who will most benefit from receiving chemotherapy plus bevacizumab treatment in first-line therapy. Additionally, our data reinforce the notion of a close association between the RAAS and the anti-angiogenic response in cancer.https://www.mdpi.com/2072-6694/14/13/3054VEGF-Aangiotensin-converting enzymecolorectal canceranti-angiogenic drugbevacizumabprognosis |
| spellingShingle | M. José Ortiz-Morales Marta Toledano-Fonseca Rafael Mena-Osuna M. Teresa Cano Auxiliadora Gómez-España Juan R. De la Haba-Rodríguez Antonio Rodríguez-Ariza Enrique Aranda Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab Cancers VEGF-A angiotensin-converting enzyme colorectal cancer anti-angiogenic drug bevacizumab prognosis |
| title | Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab |
| title_full | Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab |
| title_fullStr | Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab |
| title_full_unstemmed | Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab |
| title_short | Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab |
| title_sort | basal vegf a and ace plasma levels of metastatic colorectal cancer patients have prognostic value for first line treatment with chemotherapy plus bevacizumab |
| topic | VEGF-A angiotensin-converting enzyme colorectal cancer anti-angiogenic drug bevacizumab prognosis |
| url | https://www.mdpi.com/2072-6694/14/13/3054 |
| work_keys_str_mv | AT mjoseortizmorales basalvegfaandaceplasmalevelsofmetastaticcolorectalcancerpatientshaveprognosticvalueforfirstlinetreatmentwithchemotherapyplusbevacizumab AT martatoledanofonseca basalvegfaandaceplasmalevelsofmetastaticcolorectalcancerpatientshaveprognosticvalueforfirstlinetreatmentwithchemotherapyplusbevacizumab AT rafaelmenaosuna basalvegfaandaceplasmalevelsofmetastaticcolorectalcancerpatientshaveprognosticvalueforfirstlinetreatmentwithchemotherapyplusbevacizumab AT mteresacano basalvegfaandaceplasmalevelsofmetastaticcolorectalcancerpatientshaveprognosticvalueforfirstlinetreatmentwithchemotherapyplusbevacizumab AT auxiliadoragomezespana basalvegfaandaceplasmalevelsofmetastaticcolorectalcancerpatientshaveprognosticvalueforfirstlinetreatmentwithchemotherapyplusbevacizumab AT juanrdelahabarodriguez basalvegfaandaceplasmalevelsofmetastaticcolorectalcancerpatientshaveprognosticvalueforfirstlinetreatmentwithchemotherapyplusbevacizumab AT antoniorodriguezariza basalvegfaandaceplasmalevelsofmetastaticcolorectalcancerpatientshaveprognosticvalueforfirstlinetreatmentwithchemotherapyplusbevacizumab AT enriquearanda basalvegfaandaceplasmalevelsofmetastaticcolorectalcancerpatientshaveprognosticvalueforfirstlinetreatmentwithchemotherapyplusbevacizumab |